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ABSTRACT
Introduction An improved understanding of factors 
explaining tuberculosis (TB) treatment response 
is urgently needed to help clinicians optimise and 
personalise treatment and assist scientists undertaking 
novel treatment regimen trials. Promising outcome proxy 
measures, including sputum bacillary load and host 
immune response, are widely reported with variable 
results. However, they have not been studied together 
in combination with antibiotic exposure. The aim of 
this observational cohort study is to investigate which 
antibiotic exposures correlate with sputum bacillary load 
and which with the host immune response. Subsequently, 
we will explore if these correlations can be used to inform 
a candidate combined biomarker predicting cure.
Methods and analysis All patients aged  ≥  18, 
diagnosed with drug- sensitive pulmonary TB (culture or 
molecular test), eligible for standard anti- TB treatment, 
at selected London, UK TB Services, will be invited to 
participate in this observational cohort study (target 
sample size=210). Patients will be asked to give blood 
for host transcriptomics and antibiotic plasma exposure, 
in addition to standard of care sputum samples for 
bacillary load. Antibiotic plasma concentrations will be 
quantified using a validated liquid chromatograph triple 
quadrupole mass spectrometer (LC- MS/MS) assay and 
sputum bacillary load by mycobacterial growth incubator 
tube time to positivity. Expression from a total of 35 
prespecified host blood genes will be quantified using 
NanoString ® . Antibiotic exposure, sputum bacillary 
load and host blood transcriptomic time series data 
will be analysed using nonlinear mixed- effects models. 
Correlations between combinations of longitudinal 
biomarkers and microbiological cure at the end of 
treatment and remaining relapse free for 1 year thereafter 
will be analysed using logistic regression and Cox 
proportional hazard models.
Ethics and dissemination The observational cohort study 
has been approved by the UK’s HRA REC (20/SW/0007). 
Written informed consent will be obtained. Results will be 
disseminated via publication, presentation and through 
engagement with institutes/companies developing novel 
anti- TB treatment combinations.
INTRODUCTION
Globally, in 2019, an estimated 10.0 (9.0–
11.0) million people fell ill with tuberculosis 
(TB). In the same year, approximately 1.2 
(range: 1.1–1.3) million and 208 000 (range: 
1 77,000–2 42, 000) HIV- negative and posi-
tive people died from TB.1 The treatment 
of TB comprises a combination of antibi-
otics to optimise the effect and mitigate the 
emergence of resistance. It currently takes 
6 months minimum to treat drug- sensitive 
TB (DS- TB) or multidrug- resistant (MDR) 
TB.2 3 However, it has been shown that for 
80% of patients, a shorter treatment dura-
tion suffices4 although there are currently 
no biomarkers that can accurately identify 
these individuals. Such a biomarker could, 
for example, help identify patients, within 
the first 2 months of treatment, that need 
to continue after the intensive phase as they 
are not responding well. It could also help 
improve the design of prospective clinical 
Strengths and limitations of this study
 ► This study explores for the first time correlations be-
tween antibiotic exposure and both sputum tubercu-
losis (TB) bacillary load and host immune response.
 ► This enables correlations between different com-
binations of longitudinal markers of TB treatment 
response and TB treatment outcome to be explored.
 ► Such correlations can form the basis for a candidate 
biomarker that predicts cure from TB during the in-
tensive phase of treatment.
 ► Sampling schedules are restricted to standard of 
care visits among a patient cohort treated for drug- 
sensitive pulmonary TB.
 ► Findings will need validation using data from pa-
tients with different forms of disease and in other 
geographical regions.
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trials investigating rationally designed effective, shorter 
and/or individualised treatment options.
Several approaches, including measuring early bacteri-
cidal activity or host immune response, to predict favour-
able outcomes, have been tested.5–7 Previous research 
shows that steeper bacterial kill- curves and bacterial kill- 
curves that are steep for longer correlate with microbio-
logical cure at the end of treatment. Reoccurrence (ie, 
reinfection and relapse) was associated with less steep 
bacterial kill- curves.8 These findings are consistent with 
work by others, which demonstrated that detectable Myco-
bacterium tuberculosis (Mtb) in sputum 2 and 3 months 
into treatment was associated with treatment outcome. 
However, the results also showed that culture conversion, 
as a predictor for treatment outcome, is not good enough 
for trial- level outcome predictions.5 The predictive value 
of culture conversion is even less helpful for individual 
patients.6
Host immune response markers such as seen in the 
whole blood transcriptome can discriminate between 
active TB disease and healthy controls.9 As the expression 
of certain gene signatures resolves during treatment of 
active TB,10 11 this information could form the basis for 
identifying a biomarker of early response to treatment. 
This has been reported in patients with DS- TB, but early 
predictions (e.g., during week 1 and week 4 of treatment) 
of microbiological cure at the end of treatment were not 
accurate enough for clinical or trial application.7
Interactions between the longitudinal markers, for 
example, antibiotic exposure, sputum bacillary load 
and host blood transcriptome within the same patient 
have to date not been evaluated, even though a combi-
nation of antibiotic exposure, sputum bacillary load and 
host immune response would be expected to follow a 
composite pattern. The aim of this study is to explore 
a combined biomarker for response to treatment of 
TB. The primary objective is to investigate correlations 
between antibiotic exposure and sputum bacillary load 
and host immune response, with a secondary objective to 
explore trends between the aforementioned correlations 
and treatment outcome.
METHODS AND ANALYSIS
This is a prospective, longitudinal and repeated- measure 
study that plans to recruit 210 drug- sensitive pulmonary 
patients with TB in London, UK. Patients will be followed 
during the 6- month treatment period at predefined visits. 
Formal follow- up visits are not usually scheduled during 
a 12- month post- treatment period, and instead patients 
are encouraged to contact the London TB Services imme-
diately when signs and symptoms of possible TB disease 
reappear. Patients will be linked to the national TB data-
base to enable monitoring for relapse or reinfection 
(table 1).
Study site selection
TB notification numbers and rates display a steady decline 
in England since 2011. The majority of TB cases is reported 
in London (2018: n=1691 and rate=19.0/100,000) and 
other major cities such as Birmingham (West Midlands 
2018: n=613 and rate=10.4/100,000). Coinfection with 
HIV is rare among patients with TB in England at 2.7% 
in 2018. Isoniazid and MDR/rifampicin resistant TB are 
also uncommon in England at 8% and 1.6% in 2018. 
Despite the most recent numbers being low in England, 
Table 1 Study design.
D: day, W: week and M: month D0 D14 W4 W8 W12 M4 M5 M6 Follow- up*
Consent  ✓   
Medical history  ✓   
Physical exam  ✓   
Bodyweight measure  ✓  ✓  ✓  ✓  ✓  ✓  ✓  ✓ 
Laboratory test†  ✓  ✓  ✓  ✓  ✓  ✓  ✓  ✓  ✓ 
Pregnancy test  ✓   
Sputum sampling‡  ✓  ✓  ✓  ✓  ✓  ✓  ✓  ✓  ✓ 
Blood plasma sampling  ✓  ✓  ✓   
Whole blood sampling  ✓  ✓  ✓  ✓  ✓ §
Medication record box¶  ✓   
*Passive follow- up phase, patients will be linked to the national TB database to enable monitoring of relapse or reinfection and are asked to 
contact the London TB Services when signs and symptoms of possible TB disease re- appear.
†Including full blood count, liver function tests (hepatic transaminases and total bilirubin), bio- chemistry (urea and electrolytes).
‡To be conducted until two consecutive negative samples; and sampling may be resumed when there are signs of treatment failure or 
relapse.
§To be performed only in case of a recurrence, that is, a positive sputum smear or culture after patient being successfully treated at month 6 
(M6).
¶Medication record box, explain how to use it at the first visit.
TB, tuberculosis.
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the prevalence of TB in London remains high compared 
with other major Western European cities.12
The relatively high prevalence of TB in London, in 
combination with well- resourced TB clinics, enables us to 
conduct this observational cohort. Serial sputum bacillary 
load quantification is common as part of standard of care, 
while drug- level measurements are now more frequent 
given their value in determining whether therapeutic 
drug levels have been achieved.13 A limited amount of 
additional measures are, therefore, needed to enable 
us to answer the proposed research questions. These 
include: whole blood sampling for host blood transcrip-
tomics and precise adherence monitoring using medica-
tion record boxes.
The London TB Services is organised into five geograph-
ical groupings. We intend to recruit from all London 
sectors. This will provide a diverse study population. The 
study started on 23 February 2021 and we expect to reach 
our target sample size in 24 months.
Participant eligibility criteria and recruitment
Individuals attending the study clinics that meet all inclu-
sion and none of the exclusion criteria are given patient 
information sheets. If the patient is willing to take part, 
then written consent will be obtained.
 ► Inclusion criteria
 – Man or woman  ≥ 18 years.
 – Sputum sample suggesting Mtb based on culture or 
molecular test.
 – Starting a pulmonary isoniazid and rifampicin sus-
ceptible Mtb treatment.
 – Permission to be linked to (Public Health England) 
PHE national TB database.
 – Willingness to attend study visits.
 – Completed written consent.
 ► Exclusion criteria
 – Pregnant or breast feeding.
 – Social/medical conditions making study participa-
tion unsafe.
 – Not eligible to start a course of DS- TB treatment.
Drug sensitivity testing at baseline is part of NHS 
standard care. This enables only patients with isoniazid 
and rifampicin susceptible Mtb infections to be enrolled.
Assessment of objectives
In order to study both primary and secondary objectives, 
this study collects, in addition to clinical data obtained 
as part of standard of care, information on adherence to 
treatment and host blood transcriptomic analysis.
Sample size assumptions
Given the primary objective, the sample size for this study 
was determined to power accurate and precise estima-
tion of nonlinear mixed- effects model parameters that 
describe longitudinal pharmacological, microbiological 
and immunological data. At a sample size of 210, there is 
power to detect a correlation  ≥ 0.19 between the different 
markers with 80% power and a 0.05 type 1 error rate.
The secondary objective aims to separate combined 
biomarkers between patients who had or had not reached 
microbiological cure at the end of treatment or had or 
had not finished treatment at 6 months, and patients who 
had or had no relapse during the first year after success-
fully finishing treatment. Assuming a 4.8% failure rate, 
defined as still on treatment after 12 months,12 accounting 
for 10% drop out,12 the study design is powered to detect 
a difference of 0.96 SDs in composite markers with 189 
patients at 80% power with 0.05 type 1 error rate.
Clinical covariates
Clinical covariates that are routinely collected as part 
of standard care will be collected from clinical notes 
and stored in a REDCap database.14 15 These covariates 
include a medical history check, physical examination 
and pregnancy test at the D0 visit and at all consecutive 
visits bodyweight and laboratory tests including full blood 
count, liver function tests (hepatic transaminases and 
total bilirubin), urea and electrolytes (table 1).
Evaluation of adherence
Patients taking part in this study will be given a medica-
tion record box to monitor the date and time that drugs 
have been taken.16 Patients will be reminded by phone 
call or text about the clinic appointment the day before, if 
they have previously forgotten to bring their medication 
record boxes with them. This will be alongside standard 
NHS care, where patients who on initial or subsequent risk 
assessment are felt to be at high risk of poor adherence 
will be offered support with a range of options including 
directly observed therapy, video observed therapy and 
dosette boxes.
Antibiotic plasma concentrations
Whole blood (0.5–1.0 mL) will be collected at ~2 hours 
postdrug intake on the D14, M2 and M6 visits (table 1). 
Plasma will be separated by centrifugation (at 1500 g for 
10 min). Samples will subsequently be stored at −70°C, 
within 24 hours after collection, until shipment on dry 
ice for analysis.
Antibiotic plasma concentrations will be quantified 
using an Liquid Chromatograph Triple Quadrupole 
Mass Spectrometer (LC- MS/MS) as per standard of care 
protocols.
Sputum bacillary load
In line with usual practice, patients will be asked to produce 
2–3 sputum samples (2.5 mL) over a 24- hour period at the 
D0, D14 and M1 visit and then monthly until two negative 
consecutive sputum samples have been obtained. Where 
possible, sputum will be induced if patients stop coughing 
prior to two negative consecutive sputum samples have 
been obtained. Sputum bacterial load will be quantified 
using mycobacterial growth incubator tube time to posi-
tivity within 48 hours of production.
Isolates at baseline and subsequent treatment failure 
isolates will be subjected to whole genome sequence 
analysis.
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Host blood gene signature expressions
Whole blood (3 mL) will be collected directly into blood 
RNA tubes from patients at D0, D14, M2 and M6 visits for 
host blood transcriptomics. Samples will be stored in the 
freezer (−20°C) until analysis.
Expression of validated gene signatures, comprising 35 
genes, will be quantified using NanoString ® .17 18
Modelling and statistics
A detailed analysis plan will be developed, but in brief, 
nonlinear mixed- effects models will be used for the 
primary objective. The first component comprises phar-
macokinetic models that characterise how the drugs 
are absorbed in, distributed through, metabolised and 
eliminated from the body.8 The second component will 
comprise a pharmacodynamic model that characterises 
clearance of bacillary load from sputum by the rate of 
elimination and the loss of steepness in bacillary killing 
over the course of treatment, that is, mono or biphasic 
decay.8 The third component comprises nonlinear 
mixed- effects models that characterise resolution of gene 
expression for selected signatures during the course of 
treatment, which may be mono or biphasic.9 17 18 All three 
model components consist of a structural model compo-
nent and variability component that separates random 
variability between patients from residual variability. With 
these three types of models and a covariate modelling 
approach, drug levels—bacterial load correlations and 
drug levels—host immune response associations will be 
characterised.19 20 Partial time series data, for example, 
patients switching treatment due to development of 
adverse events, will be retained for analysis.
A multivariate generalised logistic regression model 
will be used for the secondary objective, to explore a 
combined biomarker, comprising the aforementioned 
matrices, that best predicts microbiological cure at the 
end of treatment. The candidate combined biomarker’s 
power to predict relapse during the 12 months following 
successful treatment will also be explored using a Cox 
proportional hazard model.
All aforementioned analyses will be performed using 
k- fold validation with the training partition of a proposed 
train:test split of 70:30 to obtain a more reliable predictive 
performance of the algorithm on the test split.21 Further-
more, data from this study will need to be combined with 
that from other studies to further study the generalis-
ability of the findings.
Patient and public involvement
No patient and public involved.
Project status
The Royal Free London NHS Foundation Trust will be 
the first site to recruit patients with subsequent roll- out to 
other London sites.
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